Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

World Journal of Gastroenterology

Volumn 20, Issue 16, 2014, Pages 4745-4752

  Zhang, Yang ^a   Hu, Xiao Yu ^a   Zhong, Sen ^a   Yang, Fang ^a   Zhou, Tao You ^b   Chen, Guo ^a   Wang, Yan Yan ^a   Luo, Jian Xing ^a  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Acute on chronic liver failure; Entecavir; Hepatitis b; Lamivudine; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ENTECAVIR; LAMIVUDINE; PROTON PUMP INHIBITOR; QO; TERLIPRESSIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; VIRUS REACTIVATION; ACUTE-ON-CHRONIC LIVER FAILURE; ANALOGS AND DERIVATIVES; BLOOD; CHINA; COMPLICATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; KAPLAN MEIER METHOD; MORTALITY; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHINA; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84899646189     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i16.4745     Document Type: Article

References (33)

1. Liu XY, Hu JH, Wang HF, Chen JM. [Etiological analysis of 1977 patients with acute liver failure, subacute liver failure and acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Zazhi 2008; 16: 772-775. [PMID: 18983776]
2. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-onchronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59: 1561-1569. [PMID: 20675694 DOI: 10.1136/ gut.2009.189639]
3. Evenepoel P, Laleman W, Wilmer A, Claes K, Maes B, Kuypers D, Bammens B, Nevens F, Vanrenterghem Y. Detoxifying capacity and kinetics of prometheus--a new extracorporeal system for the treatment of liver failure. Blood Purif 2005; 23: 349-358. [PMID: 16020951 DOI: 10.1159/000086885]
4. Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 2012; 44: 166-171. [PMID: 21978580 DOI: 10.1016/j.dld.2011.08.029]
5. Sass DA, Shakil AO. Fulminant hepatic failure. Liver Transpl 2005; 11: 594-605. [PMID: 15915484 DOI: 10.1002/lt.20435]
6. Yuan D, Liu F, Wei YG, Li B, Yan LN, Wen TF, Zhao JC, Zeng Y, Chen KF. Adult-to-adult living donor liver transplantation for acute liver failure in China. World J Gastroenterol 2012; 18: 7234-7241. [PMID: 23326128 DOI: 10.3748/wjg. v18.i48.7234]
7. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10: 29-34. [PMID: 2307827 DOI: 10.1016/0168-8278(90)90069-4]
8. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-1843. [PMID: 3569757]
9. Kumar M, Jain S, Sharma BC, Sarin SK. Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B. Dig Dis Sci 2006; 51: 594-599. [PMID: 16614972 DOI: 10.1007/s10620-006-3175-2]
10. Polson J, Lee WM, American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197. [PMID: 15841455 DOI: 10.1002/hep.20703]
11. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003; 38: 322-327. [PMID: 12586298 DOI: 10.1016/S0168-8278(02)00419-1]
12. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010; 25: 583-590. [PMID: 19968744 DOI: 10.1111/ j.1440-1746.2009.06089.x]
13. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 1618-1628. [PMID: 12135009 DOI: 10.1111/j.1572-0241.2002.05819.x]
14. Chan HL, Wong VW, Hui AY, Tsang SW, Chan JL, Chan HY, Wong GL, Sung JJ. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006; 11: 465-471. [PMID: 16856620]
15. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007; 60: 201-205. [PMID: 17556353 DOI: 10.1093/ jac/dkm175]
16. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514. [PMID: 19280622 DOI: 10.1002/hep.22841]
17. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. [Diagnostic and treatment guidelines for liver failure]. Zhonghua Gan Zang Bing Zazhi 2006; 14: 643-646. [PMID: 16995974]
18. Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci 2010; 55: 2373-2380. [PMID: 20512414 DOI: 10.1007/ s10620-010-1257-7]
19. Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis. Ann Hepatol 2013; 12: 364-372. [PMID: 23619252]
20. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Erlbaum, Lawrence Erlbaum Associates, 1988
21. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-435. [PMID: 6724511 DOI: 10.1002/ hep.1840040313]
22. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871. [PMID: 10733541 DOI: 10.1053/ he.2000.5852]
23. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863-1869. [PMID: 10347131 DOI: 10.1002/hep.510290626]
24. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002; 22: 121-126. [PMID: 12028405 DOI: 10.1034/j.1600-0676.2002.01579.x]
25. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893. [PMID: 20683932 DOI: 10.1002/hep.23785]
26. Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 2008; 23: 1242-1249. [PMID: 18637053 DOI: 10.1111/ j.1440-1746.2008.05484.x]
27. Chen L, Zheng CX, Lin MH, Gan QR, Lin RS, Gao HB, Huang JR, Pan C. [The impact of early rapid virological response on the outcomes of hepatitis B associated acute on chronic liver failure during antiviral treatment]. Zhonghua Gan Zang Bing Zazhi 2011; 19: 734-737. [PMID: 22409843 DOI: 10.3760/cma.j.issn.1007-3418.2011.10.004]
28. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775-783. [PMID: 19957031 DOI: 10.1007/ s10620-009-1060-5]
29. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006. [PMID: 19937695 DOI: 10.1002/hep.23346]
30. Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol 2012; 18: 2443-2451. [PMID: 22654441 DOI: 10.3748/wjg.v18.i20.2443]
31. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774-780. [PMID: 21294143 DOI: 10.1002/hep.24109]
32. Shaikh T, Cooper C. Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 2012; 26: 148-150. [PMID: 22408765]
33. Organization Committee of 13th Asia-Pacific Congress of Clinical Microbiology and Infection. 13th Asia-Pacific Congress of Clinical Microbiology and Infection Consensus Guidelines for diagnosis and treatment of liver failure. Hepatobiliary Pancreat Dis Int 2013; 12: 346-354. [PMID: 23924491 DOI: 10.1016/S1499-3872(13)60055-7]